TCIM
ALXN

TIAA CREF Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

TIAA CREF Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$450M Buy
3,328,824
+1,401,686
+73% +$174M 0.32% 61
2018
Q4 		$188M Sell
1,927,138
-476,998
-20% -$56.4M 0.15% 142
2018
Q3 		$334M Sell
2,404,136
-221,989
-8% -$27.8M 0.22% 99
2018
Q2 		$326M Sell
2,626,125
-879,659
-25% -$103M 0.22% 98
2018
Q1 		$391M Sell
3,505,784
-331,135
-9% -$39.6M 0.26% 83
2017
Q4 		$459M Buy
3,836,919
+414,969
+12% +$50.5M 0.3% 68
2017
Q3 		$480M Buy
3,421,950
+201,989
+6% +$27.4M 0.33% 64
2017
Q2 		$392M Buy
3,219,961
+955,578
+42% +$111M 0.28% 79
2017
Q1 		$275M Sell
2,264,383
-292,305
-11% -$37.7M 0.2% 104
2016
Q4 		$313M Buy
2,556,688
+81,702
+3% +$10M 0.23% 91
2016
Q3 		$303K Sell
2,474,986
-477,219
-16% -$61.4M 0.19% 107
2016
Q2 		$345M Buy
2,952,205
+762,010
+35% +$108M 0.26% 81
2016
Q1 		$305M Sell
2,190,195
-174,586
-7% -$25.6M 0.23% 93
2015
Q4 		$451M Buy
2,364,781
+310,630
+15% +$54.3M 0.34% 65
2015
Q3 		$321M Sell
2,054,151
-1,036,671
-34% -$189M 0.25% 81
2015
Q2 		$559M Buy
3,090,822
+730,651
+31% +$126M 0.4% 50
2015
Q1 		$409M Sell
2,360,171
-92,922
-4% -$16.8M 0.28% 72
2014
Q4 		$454M Buy
2,453,093
+414,497
+20% +$76.8M 0.32% 62
2014
Q3 		$338M Buy
2,038,596
+47,551
+2% +$7.81M 0.24% 85
2014
Q2 		$311M Buy
1,991,045
+238,999
+14% +$37.7M 0.22% 101
2014
Q1 		$267M Sell
1,752,046
-1,041,224
-37% -$166M 0.19% 110
2013
Q4 		$372M Sell
2,793,270
-394,715
-12% -$47.4M 0.27% 81
2013
Q3 		$370M Buy
3,187,985
+511,703
+19% +$56.1M 0.29% 69
2013
Q2 		$247M Buy
+2,676,282
New +$258M 0.2% 101

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TIAA CREF Investment Management's ALXN Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Alexion Pharmaceuticals (ALXN) stake by 73% in Q1 2019, buying an estimated $174M and bringing the position to 3,328,824 shares worth $450M. The position accounts for 0.32% of the portfolio, ranked #61.

TIAA CREF Investment Management first reported a position in ALXN in Q2 2013 and has held it in 24 quarters since. The position peaked at $559M in Q2 2015. 611 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

  • TIAA CREF Investment Management held 3,328,824 shares of Alexion Pharmaceuticals worth $450M as of Q1 2019.
  • TIAA CREF Investment Management bought 1,401,686 Alexion Pharmaceuticals shares in Q1 2019, an estimated $174M.
  • Alexion Pharmaceuticals made up 0.32% of TIAA CREF Investment Management's portfolio in Q1 2019, its #61 holding.
  • TIAA CREF Investment Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Alexion Pharmaceuticals position peaked at $559M in Q2 2015.
  • 611 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.